Novel Inhibitor of advanced glycation end-products for the prevention of Diabetic Retinopathy (DRP)
Diabetic retinopathy is the most prevalent cause of blindness and vision loss in people under age 75 with no specific treatment option.
AVVA’s research extends to the properties of 2 pyridoxine derivative molecules, currently under synthesis for the use in proof-of-concept preclinical studies.



Inventors

Yuriy G. Shtyrlin, PhD,
Doctor of Science (Chemistry),
Assistant professor,
Director of the Research Center of Pharmacy of Kazan Federal University

Alexey D. Strelnik, PhD,
Senior Researcher of the Department of Medical Chemistry of the Research Center of Pharmacy of Kazan Federal University

Marya N. Agaphonova, PhD,
Senior Researcher of the Department of Medical Chemistry of the Research Center of Pharmacy of Kazan Federal University

Oksana V. Bondar, PhD,
Senior Researcher of the Department of Medical Chemistry of the Research Center of Pharmacy of Kazan Federal University